New York, Feb 17, 2026, 14:48 EST — Regular session
- Thermo Fisher slipped just under 0.1% in afternoon trading, trailing a healthcare sector that struggled for clear direction.
- Danaher shares slipped after the company announced plans to acquire Masimo, putting renewed spotlight on M&A activity in diagnostics and tools.
- Eyes are on Thermo’s Clario financing, along with the upcoming batch of sector earnings, as investors hunt for signs of demand.
Thermo Fisher Scientific was recently off just $0.43 to $504.39, with shares hardly budging in afternoon trade Tuesday.
The stock’s quiet stretch coincides with renewed deal chatter in the life-sciences sector, following Danaher’s $9.9 billion Masimo buyout—an announcement that has split opinion on Wall Street so far. Analysts at J.P. Morgan described the medtech pick as “surprising.” Bernstein’s Christian Moore, though, suggested the transaction could make more sense as time passes. Reuters
Thermo Fisher’s got a deal weighing on it. Earlier this month, the company priced $3.8 billion in USD-denominated senior notes, part of the financing for its planned buyout of clinical-trials data outfit Clario. Shares have dropped about 6% since large-cap tools stocks sold off last week.
According to an SEC prospectus supplement related to the debt offering, Thermo Fisher indicated the notes should settle on or about Feb. 12. Interest will start accruing from that date, with payments scheduled twice a year.
Thermo Fisher has struck a deal to acquire Clario for $8.875 billion in cash upfront, with possible additional payouts linked mostly to how Clario performs, the company said in its announcement.
End-demand is still the main worry for investors. Back in late January, Thermo Fisher warned its 2026 profit might fall short of expectations, citing weaker U.S. academic research funding—even though quarterly numbers actually beat estimates, thanks to pharmaceutical customers snapping up drug-development tools, according to Reuters.
Danaher slipped roughly 3.4% Tuesday. Agilent dropped about 1.2%, while Illumina edged down just 0.1%.
Thermo Fisher isn’t out of the woods yet. Any holdup in the Clario deal, volatility in borrowing costs, or sharper cuts in government and university budgets could spark fresh questions about when tools demand stabilizes this year.
This week, Agilent steps up with results on Feb. 25—a key check-in for those tracking lab spending trends and order flows. Over at Thermo Fisher, next earnings land April 22, according to market calendars.
